ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 0994

Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus

Michelle Petri1, Daniel Joyce2, Kristin Haag2, Andrea Fava3, Daniel W. Goldman1, Diana Zhong2, Shaoming Xiao4, Aaron M. Milstone2 and Laurence S Magder5, 1Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University, Baltimore, MD, 4Johns Hopkins School of Public Health, Baltimore, MD, 5University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD

Meeting: ACR Convergence 2022

Keywords: COVID-19, immunology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: The risk of COVID-19 infection is increased in patients with systemic lupus erythematosus (SLE), and immunosuppressive medications including corticosteroids impact the risk. Furthermore, immunosuppressive medications may reduce the effectiveness of COVID-19 vaccination. Consensus documents have suggested management strategies on handling immunosuppressive medications to increase vaccine efficacy, but the benefit of such strategies has not been proven.

Methods: We collected information on COVID infection, COVID vaccination history, and COVID antibodies in the Hopkins Lupus Cohort, a longitudinal cohort with structured quarterly visits. A cohort of healthcare workers was used for comparison. SARS-CoV-2 IgG was measured by ELISA (Euroimmun). We included only those receiving either a Pfizer or Moderna vaccination and excluded those with a history of COVID infection. Outcome measures included: SARS-CoV-2 antibody IgG levels after vaccination over time in both cohorts; and effect of immunosuppressive medications on post-vaccine IgG levels in SLE patients.

Results: The analysis was based on 334 SLE patients (196 Pfizer, 138 Moderna) and 1887 health care workers (1530 Pfizer and 357 Moderna). SLE patients on immunosuppressive medications had lower post-vaccine IgG levels than SLE patients who were not; but both groups had lower levels than healthcare workers (Figure 1 and Table 1). Holding mycophenolate for one week after vaccine increased post-vaccine IgG levels significantly. In multiple variable models, mycophenolate mofetil, tacrolimus, and belimumab all significantly reduced antibody response to vaccination (Table 2).

Conclusion: SLE patients, regardless of background immunosuppressive therapy, had lower vaccine IgG levels than healthcare workers. Belimumab, tacrolimus and mycophenolate use significantly reduced IgG response to vaccine. Holding mycophenolate for one week improved vaccine efficacy, providing clinical benefit on vaccine response, without leading to clinical flares.

Supporting image 1

Figure 1: Estimated mean IgG measure over time since 2nd vaccination (based on Loess smoothing), by cohort and use of immunosuppressants (IS).

Supporting image 2

Table 1: Effect of medications taken at the time of first vaccination on SARS-CoV_2 IgG levels among SLE patients.

Supporting image 3

Table 2: Estimated effect of treatment at time of vaccination on mean IgG based on a multivariable regression model


Disclosures: M. Petri, Exagen, AstraZeneca, Alexion, Amgen, AnaptysBio, Argenx, Aurinia, Biogen, Caribou Biosciences, CVS Health, EMD Serono, Eli Lilly, Emergent Biosolutions, GlaxoSmithKline (GSK), IQVIA, Janssen, Kira Pharmaceuticals, MedShr, Sanofi, SinoMab, Thermofisher, BPR Scientific Advisory Committee; D. Joyce, None; K. Haag, None; A. Fava, Sanofi; D. Goldman, None; D. Zhong, None; S. Xiao, None; A. Milstone, Merck; L. Magder, None.

To cite this abstract in AMA style:

Petri M, Joyce D, Haag K, Fava A, Goldman D, Zhong D, Xiao S, Milstone A, Magder L. Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/effect-of-immunosuppression-on-covid-vaccination-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-immunosuppression-on-covid-vaccination-in-systemic-lupus-erythematosus/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology